Research Topics
Genomes and Genes | Khandan KeyomarsiSummaryAffiliation: The University of Texas Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Low-molecular-weight cyclin E: the missing link between biology and clinical outcomeSaid Akli
Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Breast Cancer Res 6:188-91. 2004..These findings suggest that high levels of LMW isoforms of cyclin E not only can predict failure to endocrine therapy but also are true prognostic indicators because of their influence on cell proliferation and genetic instability...- Cyclin E and survival in patients with breast cancerKhandan Keyomarsi
Department of Experimental Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston 77030 4095, USA
N Engl J Med 347:1566-75. 2002..Cyclin E, a regulator of the cell cycle, affects the behavior of breast-cancer cells. We investigated whether levels of cyclin E in the tumor correlated with survival among patients with breast cancer... - Semi-high throughput method of measuring proteasome inhibition in vitro and in cultured cellsKhandan Keyomarsi
Department of Experimental Radiation Oncology, The University of Texas M D Anderson Cancer Center, P O Box 66, 1515 Holcombe Blvd, Houston, TX 77030, USA
Cell Biol Toxicol 27:123-31. 2011..In summary, the four-step assay protocol can easily be adapted into a high throughput format to rapidly screen unknown inhibitors... - Cyclin E deregulation impairs mitotic progression through premature activation of Cdc25CRozita Bagheri-Yarmand
Department of Experimental Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer Res 70:5085-95. 2010..These results suggest that the high levels of LMW-E isoforms found in breast cancer may contribute to cellular transformation and genomic instability by impairing mitotic progression involving Cdc25C... - Low molecular weight cyclin E overexpression shortens mitosis, leading to chromosome missegregation and centrosome amplificationRozita Bagheri-Yarmand
Department of Experimental Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer Res 70:5074-84. 2010..These results suggest that LMW-E overexpression leads to higher centrosome numbers in breast cancer, which is a prerequisite for genomic instability... - Cyclin E deregulation is an early event in the development of breast cancerAlexandra Shaye
Department of Pathology, University of Texas, M D Anderson Cancer Center, Houston, TX, USA
Breast Cancer Res Treat 115:651-9. 2009..Our findings suggest that cyclin E deregulation is an early event in the progression from histologically benign mammary epithelial cells to invasive carcinoma and occurs through both overexpression and altered cellular localization... - Low-molecular-weight cyclin E can bypass letrozole-induced G1 arrest in human breast cancer cells and tumorsSaid Akli
Departments of Experimental Radiation Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 16:1179-90. 2010.... - Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancerSaid Akli
Department of Experimental Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
Cancer Res 64:3198-208. 2004.... - Differential regulation of elafin in normal and tumor-derived mammary epithelial cells is mediated by CCAAT/enhancer binding protein betaTomoya Yokota
Department of Experimental of Radiation Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 4095, USA
Cancer Res 67:11272-83. 2007.... - Cyclin E deregulation alters the biologic properties of ovarian cancer cellsIsabelle Bedrosian
Department of Surgical Oncology, MD Anderson Cancer Center, University of Texas, Houston, TX 77030, USA
Oncogene 23:2648-57. 2004..Therefore, in ovarian tumors, the presence of LMW cyclin E forms confers altered biologic properties. Our data provides a potential mechanism for the poor prognosis of patients with LMW cyclin E expressing tumors... - Anti-HER2 antibody trastuzumab inhibits CDK2-mediated NPAT and histone H4 expression via the PI3K pathwayXiao-Feng Le
Department of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas 77030-4009, USA
Cell Cycle 5:1654-61. 2006.... - Low molecular weight cyclin E is specific in breast cancer and is associated with mechanisms of tumor progressionHannah Wingate
Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Cell Cycle 8:1062-8. 2009..The LMW isoforms of cyclin E are tumor specific, and are biochemically and biologically distinct from the full-length cyclin E which could provide a novel role in breast cancer progression... - Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancerRoshan Agarwal
The University of Texas M D Anderson Cancer Center MDACC, Houston, Texas, USA
Clin Cancer Res 15:3654-62. 2009..We studied the expression levels of cyclins B1, D1, and E1 and the implications of cyclin overexpression for patient outcomes in distinct breast cancer subtypes defined by clinical variables and transcriptional profiling... - The tumor-specific hyperactive forms of cyclin E are resistant to inhibition by p21 and p27Hannah Wingate
Department of Experimental Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4095, USA
J Biol Chem 280:15148-57. 2005..Thus, the LMW forms of cyclin E may contribute to tumorigenesis through their resistance to the inhibitory activities of p21 and p27 while sequestering these CKIs from the full-length cyclin E... - Altered subcellular localization of tumor-specific cyclin E isoforms affects cyclin-dependent kinase 2 complex formation and proteasomal regulationNIKKI A DELK
Department of Experimental Radiation Oncology, University of Texas at M D Anderson Cancer Center, Houston Texas 77030, USA
Cancer Res 69:2817-25. 2009..One implication of our findings is that altered LMW-E and LMW-E/Cdk2 subcellular localization may lead to aberrant LMW-E protein interactions, regulation, and activity, ultimately contributing to LMW-E tumorigenicity... - Cdk2 is required for breast cancer mediated by the low-molecular-weight isoform of cyclin ESaid Akli
Department of Experimental Radiation Oncology, University of Texas, MD Anderson Cancer Center, TX, USA
Cancer Res 71:3377-86. 2011..Our findings establish a requirement for Cdk2 in LMW-cyclin E-mediated mammary tumorigenesis, arguing that human breast tumors overexpressing LMW-cyclin E are prime candidates for anti-Cdk2 therapy... - Absence of pRb facilitates E2F1-induced apoptosis in breast cancer cellsBaohua Sun
Department of Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Cell Cycle 9:1122-30. 2010..Therefore, we conclude that in the absence of Rb, E2F1 overexpression results in apoptosis, not proliferation, and that this effect is independent of p53... - Cyclin E and its low molecular weight forms in human cancer and as targets for cancer therapySaid Akli
Department of Experimental Radiation Oncology; UT-MD Anderson Cancer Center, Houston, Texas 77030-4095, USA
Cancer Biol Ther 2:S38-47. 2003.... - Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathwaySaid Akli
Department of Experimental Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Cancer Res 67:7212-22. 2007..Therefore, LMW cyclin E overexpression strongly selects for spontaneous inactivation of the ARF-p53 pathway in vivo, canceling its protective checkpoint function and accelerating progression to malignancy... - Autophagy: a novel mechanism of synergistic cytotoxicity between doxorubicin and roscovitine in a sarcoma modelLaura A Lambert
Departments of Surgical Oncology, Experimental Radiation Oncology, and Systems Biology, University of Texas M D Anderson Cancer Center, Houston, Texas
Cancer Res 68:7966-74. 2008..Further investigation of this enhanced cytotoxicity as a treatment strategy for sarcomas is warranted... - Cyclin E-associated kinase activity predicts response to platinum-based chemotherapyIsabelle Bedrosian
Department of Surgical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 13:4800-6. 2007..We hypothesized that cyclin E deregulation would predict for responsiveness to platinum-based regimens in ovarian cancer patients... - The low molecular weight cyclin E isoforms augment angiogenesis and metastasis of human melanoma cells in vivoElise Bales
Huffington Center on Aging, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
Cancer Res 65:692-7. 2005..Together, these results indicate that the LMW cyclin E forms are functional and likely act as regulators of human melanoma tumor progression and invasion... - Farnesyl and geranylgeranyl transferase inhibitors induce G1 arrest by targeting the proteasomeEkem T Efuet
Department of Experimental Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Cancer Res 66:1040-51. 2006.... - DEAR1 is a dominant regulator of acinar morphogenesis and an independent predictor of local recurrence-free survival in early-onset breast cancerSteven T Lott
Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
PLoS Med 6:e1000068. 2009.... - Targeting low molecular weight cyclin E (LMW-E) in breast cancerAngela Nanos-Webb
Department of Experimental Radiation Oncology, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Breast Cancer Res Treat 132:575-88. 2012..Clinically, the combination of CDK inhibitors and chemotherapy such as Doxorubicin provides a viable personalized treatment strategy for those breast cancer patients whose tumors express the LMW-E... - LMW-E/CDK2 Deregulates Acinar Morphogenesis, Induces Tumorigenesis, and Associates with the Activated b-Raf-ERK1/2-mTOR Pathway in Breast Cancer PatientsMylinh T Duong
Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
PLoS Genet 8:e1002538. 2012..The b-Raf-ERK1/2-mTOR signaling pathway is aberrantly activated in breast cancer and can be suppressed by combination treatment with roscovitine plus either rapamycin or sorafenib... - Deregulation of cyclin E meets dysfunction in p53: closing the escape hatch on breast cancerMichelle Craig Barton
Department of Biochemistry and Molecular Biology, University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
J Cell Physiol 209:686-94. 2006..To determine how this escape hatch is opened and, ultimately, how to close it, we must understand the networks of normal signaling and processing in a cell and where they intersect... - Cell cycle deregulation in breast cancer: insurmountable chemoresistance or Achilles' heel?Laura Lambert
Department of Surgical Oncology, University of Texas, MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, Texas 77030, USA
Adv Exp Med Biol 608:52-69. 2007..The mechanisms and effects of the deregulation of cyclin E in breast cancer are reviewed and novel approaches to circumventing chemoresistance through abrogation of the malignant cell cycle are proposed... - The neutrophil elastase inhibitor elafin triggers rb-mediated growth arrest and caspase-dependent apoptosis in breast cancerJoseph A Caruso
Departments of Experimental Radiation Oncology and Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4095, USA
Cancer Res 70:7125-36. 2010..Our findings suggest that elafin could be engineered as a therapeutic modality to treat breast cancer without toxicity to normal proliferating cells... - The double-stranded RNA-activated protein kinase mediates radiation resistance in mouse embryo fibroblasts through nuclear factor kappaB and Akt activationUrs von Holzen
Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 13:6032-9. 2007..There have been no reports to date about the role of PKR in radiation sensitivity... - Role of cell cycle in mediating sensitivity to radiotherapyTimothy M Pawlik
Department of Surgical Oncology, University of Texas M. D. Anderson Cancer Center, Box 66, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Int J Radiat Oncol Biol Phys 59:928-42. 2004..We describe how cell cycle and DNA damage checkpoint control relates to exposure to ionizing radiation... - The differential staurosporine-mediated G1 arrest in normal versus tumor cells is dependent on the retinoblastoma proteinMollianne McGahren-Murray
Department of Experimental Radiation Oncology, M.D. Anderson Cancer Center, Houston, TX 77030-4095, USA
Cancer Res 66:9744-53. 2006.... - The low molecular weight (LMW) isoforms of cyclin E deregulate the cell cycle of mammary epithelial cellsHannah Wingate
Department of Experimental Radiation Oncology, UT MD Anderson Cancer Center, Houston, Texas 77030-4095, USA
Cell Cycle 2:461-6. 2003..These results suggest that overexpression of the LMW forms of cyclin E is mitogenic, stimulating the cells to progress through the cell cycle much more efficiently than the full length cyclin E... - Synchronization of the cell cycle using lovastatinSonia Javanmoghadam-Kamrani
Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Cell Cycle 7:2434-40. 2008..Due to its level of synchrony and high yield of synchronous populations of cells, Lovastatin method of cell synchronization can be used for examining gene expression patterns in a variety of different cell lines... - Cyclin E as a prognostic and predictive marker in breast cancerKelly K Hunt
Department of Surgical Oncology, The University of Texas, M.D. Anderson Cancer Center, Houston, TX 77030, USA
Semin Cancer Biol 15:319-26. 2005..Here we discuss the role of cyclin E as a prognostic marker and predictive factor in breast cancer management and the potential to use this marker as a target for therapy... - Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancerAstrid M Eder
Department of Molecular Therapeutics, M D Anderson Cancer Center, University of Texas, Houston, TX 77030, USA
Proc Natl Acad Sci U S A 102:12519-24. 2005..These results implicate PKCiota as a potential oncogene in ovarian cancer regulating epithelial cell polarity and proliferation and suggest that PKCiota is a novel target for therapy... - Selective protection of normal proliferating cells against the toxic effects of chemotherapeutic agentsKhandan Keyomarsi
Department of Experimental Radiation Oncology, Breast Cancer Research Program, UT MD Anderson Cancer Center, Houston, TX 77030, USA
Prog Cell Cycle Res 5:527-32. 2003..Such differences also emphasize the need for the application of multiple drugs, with different modes of action... - Cyclin E is a more powerful predictor of breast cancer outcome than proliferationKhandan Keyomarsi
Nat Med 9:152. 2003 - Activation of cyclin-dependent kinase 2 by full length and low molecular weight forms of cyclin E in breast cancer cellsRichard M Harwell
Division of Molecular Medicine, Wadsworth Center, SUNY Albany, Albany, NY 12201 0509, USA
J Biol Chem 279:12695-705. 2004..CDK2 complexes leading to G(1)/S deregulation and tumor progression...
Research Grants
- Proeolytic Processing of Cyclin E in Breast CancerKhandan Keyomarsi; Fiscal Year: 2011..As such, a targeted and personalized therapy can be justified for those patients who currently do not have such treatment strategies available to them. ..
- Proteolytic Processing of Cyclin E in Breast CancerKhandan Keyomarsi; Fiscal Year: 2009....
- Proteolytic Processing of Cyclin E in Breast CancerKhandan Keyomarsi; Fiscal Year: 2007..abstract_text> ..
- Proteolytic Processing of Cyclin E in Breast CancerKhandan Keyomarsi; Fiscal Year: 2004..This new understanding of tumor specific cyclin E deregulation may lead to development of novel prognostic markers and therapeutic targets for breast cancer-the second leading cause of cancer deaths of women in this country. ..
- Proteolytic Processing of Cyclin E in Breast CancerKhandan Keyomarsi; Fiscal Year: 2010....